Evidence map›Paper›PMID 31077205›Full record

ArticleJournal of translational medicine2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, Omid Hamid, Hussein A Tawbi, Alexander van Akkooi, Alessandro Testori, Corrado Caracò, Igor Puzanov, Francesco Perrone

Open access · goldAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Paolo A AsciertoUnit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.ORCID 0000-0002-8322-475X
Paolo BruzziClinical Epidemiology Unit, University Hospital "San Martino", Genoa, Italy.
Alexander EggermontInstitut Gustave Roussy Villejuif, Paris-Sud, VilleJuif, Paris, France.
Omid HamidClinical Research and Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
Hussein A TawbiMelanoma Clinical Research & Early Drug Development, Melanoma Medical Oncology, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, TX, USA.
Alexander van AkkooiDepartment of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, The Netherlands.
Alessandro TestoriSurgical Group, EORTC Melanoma Group, Brussels, Belgium.
Corrado CaracòDepartment Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.
Igor PuzanovDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Francesco PerroneClinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITAngeles Clinic and Research Institute · USEuropean Organisation for Research and Treatment of Cancer · BEInstitut Gustave Roussy · FRMartin University · USRoswell Park Comprehensive Cancer Center · USThe Netherlands Cancer Institute · NLThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Indexed as

Chemotherapy, AdjuvantCTLA-4 AntigenEndpoint DeterminationHumansItalyMelanomaProgrammed Cell Death 1 ReceptorSurvival AnalysisCTLA-4 AntigenProgrammed Cell Death 1 ReceptorAdjuvantAnti-CTLA-4Anti-PD-1BRAF inhibitorImmunotherapyMEK inhibitorMelanomaNeoadjuvantTargeted therapy

Identifiers

PMID31077205
PMCPMC6509811
OpenAlexW2946833475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.